11 news items
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
COYA
20 Jun 24
of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
COYA
11 Jun 24
, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
COYA
3 Jun 24
1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
COYA
28 May 24
; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing
Coya Therapeutics Completes Controlled Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer's Disease
COYA
22 May 24
the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with mild-to-moderate Alzheimer's disease (AD) over
z3nnu i9rhfuh
COYA
22 May 24
-controlled study (funded by the Gates Foundation and Alzheimer's Association) evaluates the safety and tolerability, biological activity
fcdhjaum7v
COYA
20 May 24
evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured
y2x625b
COYA
9 May 24
preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our
ben1o o34rlaav0uyee3z75fu90
COYA
26 Apr 24
immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety
2gwwpbd4zo4am2vjoufkfkq3rifbx eaf1cs9lzv8pq3yfddsbezn77max1
COYA
18 Apr 24
product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our
yferz828mqqjndxbu izjo0zd1mpa1lmkqt
COYA
8 Apr 24
. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum
- Prev
- 1
- Next